All Infectious Disease articles – Page 6
-
NewsFungal toxin offers colonization support - in small doses
The yeast fungus Candida albicans not only uses the toxin candidalysin to cause infections, but also to colonize the oral mucosa inconspicuously – but only in finely balanced amounts. Too little toxin prevents oral colonization, too much triggers the immune system.
-
NewsTwo-drug combination shows promise in helping heal chronic wounds
By adding small doses of a simple molecule called chlorate to standard antibiotics, researchers foundthe combination proved 10,000 times more effective at killing bacterial cells in the lab than single-drug antibiotics.
-
NewsInactive H5N1 influenza virus in pasteurized milk poses minimal health risks
Proteins and genetic material from H5N1 influenza viruses have been found in pasteurized milk in the United States, but a study shows those inactive viral pieces represent little to no health risk. H5N1-contaminated milk that was pasteurized did not significantly affect the immune system.
-
NewsGlobal Virus Network launches multi-country mpox diagnostic evaluation to close global preparedness gaps
The Global Virus Network has initiated one of the first coordinated, multi-country evaluations of rapid point-of-care mpox diagnostics, a critical step to prevent resurgence and ensure the world is better prepared for future epidemics.
-
NewsNew study supports gene-tailored radiation doses to treat HPV+ throat cancer
Genetic testing can identify patients with HPV-positive throat cancer who may benefit from lower radiation doses, according to a new study that builds on a growing body of evidence that radiation treatment can be personalized using tumor genomics.
-
NewsStartling images show how antibiotic pierces bacteria’s armor
Researchers have shown for the first time how life-saving antibiotics called polymyxins pierce the armour of harmful bacteria. They showed how Polymyxin B rapidly caused bumps and bulges to break out on the surface of an E. coli cell, followed by the bacterium shedding its outer armour.
-
NewsBeyond viruses: Expanding the fight against infectious diseases
The newly renamed Gladstone Infectious Disease Institute has broadened its mission to address global health threats ranging from antibiotic resistance to infections that cause chronic diseases.
-
NewsDespite increase in U.S. cases, worry about West Nile virus remains low
Despite this season’s growing number of cases, relatively few Americans worry about becoming infected by West Nile or by dengue fever, another mosquito-borne illness, according to a survey of nearly 1,700 U.S. adults.
-
NewsVirologist leading team to bolster Canada’s ability to respond to future pandemics, public health emergencies
With $3M in new federal funding over two years, University of Ottawa Faculty of Medicine molecular virologist Dr. Marc-André Langlois and a multidisciplinary team of collaborators will be a vital part of Canada’s ability to respond effectively to infectious disease threats & future pandemics.
-
NewsRSV vaccines safe and effective, Cochrane review finds
A new Cochrane review demonstrates that vaccines for respiratory syncytial virus (RSV) are both safe and effective in protecting vulnerable groups that are most at risk of serious illness, including older adults and infants.
-
NewsMeta-analysis: COVID-19 vaccination during pregnancy is safe and beneficial for mother and infant
Vaccination is associated with better neonatal outcomes without added maternal risk, according to research presented during the American Academy of Pediatrics 2025 National Conference & Exhibition.
-
NewsIn pregnant mice with severe flu, harmful molecules can breach fetal barriers
A new study shows, for the first time, that severe flu infection in pregnant mice leads to a breakdown in placental and brain barriers, leading to the accumulation of potentially harmful molecules in the fetal brain. Fibrinogen can pass into developing fetal brains.
-
NewsHeadspace invaders: How mosquito-borne viruses breach the brain’s defenses
Using a stem cell-based model of the human blood-brain barrier, researchers compared two closely related Sindbis virus strains — one brain-invading and one not — and found that small changes in viral surface proteins called glycoproteins dictate whether the virus can cross.
-
NewsOkinawan marine sponges yield promising treatment for leishmaniasis
A family of compounds called onnamides shows remarkable potential against the parasite that causes a neglected tropical disease.
-
NewsTrojan horse: Amoebae as carriers for human Norovirus and Adenovirus
A new study reveals that common waterborne amoebae can ingest and protect human viruses, extending their environmental persistence. Human norovirus and human adenovirus can enter and persist within FLA.
-
NewsStudy models how human behavior, lockdowns and restrictions shaped COVID’s spread
Researchers employed computer modeling and large datasets to better understand how COVID-19 was transmitted in one community in South Africa during the course of the worldwide pandemic.
-
NewsNew study finds dried blood spot test reliably detects congenital CMV at birth
New research confirms that testing for congenital cytomegalovirus (cCMV) at birth using the routinely collected dried blood spot (DBS) is a reliable and effective method to identify newborns at risk for long-term developmental challenges.
-
NewsStudy reveals how tick-borne encephalitis virus enters cells
The protein on human cells that tick-borne encephalitis virus (TBEV) uses for infection has now been identified—a major step toward understanding how TBEV causes neurological disease and for developing antiviral drugs.
-
NewsScientists develop a virus cocktail to combat superbugs
Researchers have developed a bespoke phage therapy, Entelli-02, a five-phage cocktail designed specifically to target Enterobacter cloacae complex (ECC), a group of bacteria responsible for severe, often difficult-to-treat infections.
-
News NIH grant to UC Riverside supports research on dangerous emerging virus
Researchers have been awarded an NIH grant of about $3.4 million over five years to lead an international study focused on developing protective antibodies against Crimean-Congo hemorrhagic fever virus (CCHFV), a biosafety level 4 pathogen and a Category A bioterrorism agent.